Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00074867 |
The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase inhibitor is effective in the treatment of epithelial ovarian cancer, primary peritoneal serous cancer, or fallopian tube cancer for patients who have failed first line platinum-based therapy and have a persistent rising CA-125.
Condition | Intervention | Phase |
---|---|---|
Ovarian Neoplasms Peritoneal Neoplasms Fallopian Tube Neoplasms |
Drug: CP-547,632 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Recurrent Or Persistent Small-Volume Epithelial Ovarian Cancer, Primary Peritoneal Serous Cancer, Or Fallopian Tube Cancer |
Estimated Enrollment: | 29 |
Study Start Date: | October 2003 |
Estimated Study Completion Date: | September 2004 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Pfizer Investigational Site | |
LOS ANGELES, California, United States, 90095 | |
Pfizer Investigational Site | |
Santa Monica, California, United States, 90404 | |
United States, Maryland | |
Pfizer Investigational Site | |
Baltimore, Maryland, United States, 21237 | |
United States, Massachusetts | |
Pfizer Investigational Site | |
Boston, Massachusetts, United States, 02215 | |
Pfizer Investigational Site | |
Boston, Massachusetts, United States, 02114 | |
Pfizer Investigational Site | |
Boston, Massachusetts, United States, 02115 | |
United States, New York | |
Pfizer Investigational Site | |
New York, New York, United States, 10016 | |
Canada | |
Pfizer Investigational Site | |
Quebec, Canada, G1R 2J6 | |
Canada, Ontario | |
Pfizer Investigational Site | |
Hamilton, Ontario, Canada, L8V 5C2 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Study ID Numbers: | A3521003 |
Study First Received: | December 22, 2003 |
Last Updated: | November 6, 2006 |
ClinicalTrials.gov Identifier: | NCT00074867 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Fallopian Tube Cancer Digestive System Neoplasms Ovarian Neoplasms Gonadal Disorders Genital Neoplasms, Female Endocrine System Diseases Urogenital Neoplasms Ovarian Diseases Ovarian Epithelial Cancer Abdominal Neoplasms Fallopian Tube Neoplasms |
Recurrence Fallopian Tube Diseases Genital Diseases, Female Digestive System Diseases Peritoneal Diseases Ovarian Cancer Gastrointestinal Neoplasms Endocrinopathy Peritoneal Neoplasms Endocrine Gland Neoplasms |
Digestive System Neoplasms Ovarian Neoplasms Gonadal Disorders Genital Neoplasms, Female Endocrine System Diseases Urogenital Neoplasms Ovarian Diseases Abdominal Neoplasms Fallopian Tube Neoplasms |
Fallopian Tube Diseases Adnexal Diseases Genital Diseases, Female Neoplasms Digestive System Diseases Neoplasms by Site Peritoneal Diseases Peritoneal Neoplasms Endocrine Gland Neoplasms |